(Q40761921)

23 September 2017

title

Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha (English)

1 reference

23 September 2017

W E Aulitzky

1

1 reference

23 September 2017

W K Aulitzky

2

1 reference

23 September 2017

J Frick

3

1 reference

23 September 2017

M Herold

4

1 reference

23 September 2017

G Gastl

5

1 reference

23 September 2017

H Tilg

6

1 reference

23 September 2017

M Berger

7

1 reference

23 September 2017

C Huber

8

1 reference

23 September 2017

publication date

1 June 1990

1 reference

23 September 2017

1 reference

23 September 2017

volume

180

1 reference

23 September 2017

issue

4-5

1 reference

23 September 2017

page(s)

385-394

1 reference

A phase I clinical trial of recombinant DNA gamma interferon

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Immune interferon: a pleiotropic lymphokine with multiple effects

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Activation of human macrophages. Comparison of other cytokines with interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Autocrine secretion of tumor necrosis factor under the influence of interferon-gamma amplifies HLA-DR gene induction in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Detection of circulating tumor necrosis factor after endotoxin administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

A tumor necrosis factor binding protein is present in human biological fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2811%2980300-1

7 January 2021

10.1016/S0171-2985(11)80300-1

Identifiers

DOI

0 references

1 reference